Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Palbociclib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms CYCLIGIST
- 29 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2019.
- 29 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Apr 2018.
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.